Navigation Links
OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for Second Quarter 2013
Date:8/8/2013

BOTHELL, Wash. and VANCOUVER, British Columbia, Aug. 8, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided an overview of clinical development activities for its two product candidates, custirsen and apatorsen (OGX-427), and announced second quarter 2013 financial results.

Custirsen Program Update

  • The primary registration Phase 3 SYNERGY trial, designed to evaluate a survival benefit for custirsen in combination with first-line docetaxel chemotherapy in men with metastatic castrate-resistant prostate cancer (CRPC), completed enrollment in 2012. As a result of death events occurring more slowly than previously expected, the anticipated timing of the pre-specified number of events is currently projected to occur late in the first quarter or early in the second quarter of 2014. These survival results are expected to be announced in mid-2014. No conclusion regarding the possible outcome of the trial can or should be drawn from the fact that death events are occurring more slowly than expected.
  • Patient enrollment continues in the additional Phase 3 custirsen trials, AFFINITY and ENSPIRIT. The AFFINITY trial will evaluate the potential survival benefit of custirsen in combination with Jevtana® (cabazitaxel) as second-line chemotherapy in men with metastatic CRPC, and ENSPIRIT will evaluate the potential survival benefit of combining custirsen with docetaxel as second-line chemotherapy in patients with advanced or metastatic non-small cell lung cancer (NSCLC).
  • Apatorsen (OGX-427) Program Update

  • The Company announced that the United States Adopted Names Council has approved the use of the nonproprietary generic name "apatorsen" for OGX-427.
  • In July 2013, the Company announced that enrollment has been completed in Borealis-1™, a comp
    '/>"/>

  • SOURCE OncoGenex Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. OncoGenex Announces Multiple Trials in Progress Presentations at the 2013 ASCO Annual Meeting
    2. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013
    3. OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012
    4. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
    5. OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer
    6. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
    7. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity Growth Conference
    8. UPCOMING DEADLINE: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Vanda Pharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of August 24, 2013 to Seek a Lead Plaintiff Position
    9. Imprimis Pharmaceuticals, Inc. to Present at the Southern California Investor Conference on Thursday, August 8, 2013 at the Island Hotel in Newport Beach, CA. The presentation is scheduled to begin at 11 a.m. ET / 8 a.m. PT
    10. OPTIMER PHARMACEUTICALS SHAREHOLDER ALERT: Levi & Korsinsky Investigates Possible Breaches of Fiduciary Duty by Board of Optimer Pharmaceuticals, Inc. in Connection with Sale of Company to Cubist Pharmaceuticals, Inc.
    11. Auxilium Pharmaceuticals, Inc, Announces Second Quarter 2013 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/25/2015)... April 2015 Hospira, Inc. ... Entwicklung von Biosimilar-Behandlungen, sprach heute auf der jährlichen ... (EGA) in London über ... Verfügbarkeit von Biosimilars für Patienten. Das ... Papers mit dem Titel „Why extrapolation is ...
    (Date:4/24/2015)... 2015  Perrigo Company plc ("Perrigo" or the "Company") ... unsolicited offer from Mylan NV ("Mylan") (NASDAQ: MYL ... Perrigo for $60.00 per share in cash and 2.2 ... "Offer").  The Board previously concluded that ... the Company and its future growth prospects and was ...
    (Date:4/24/2015)... HILL, N.C. , April 24, 2015 /PRNewswire/ ... the ability of consumers to educate themselves about ... expanded the tools and techniques available to market ... Given the changing consumer marketplace, it,s imperative that ... approaches to better identify market opportunities, niches and ...
    Breaking Medicine Technology:Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 2Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 3Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 4Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 5Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 6Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 7Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 8Perrigo Rejects Mylan Unsolicited Offer 2Perrigo Rejects Mylan Unsolicited Offer 3Perrigo Rejects Mylan Unsolicited Offer 4Pharmaceutical Industry Using New Technologies to Adjust Their Marketing and Research Approaches for Consumers 2
    ... and WALTHAM, Mass., May 25, 2011 Interleukin Genetics, Inc. ... USP Hospitales now offers the innovative Heart Health Genetic ... Hospitales, the flagship hospital in Madrid, and will soon ... identifies single nucleotide variations in two Interleukin-1 (IL-1) genes ...
    ... retains Adapt IP Ventures to market XDATA,s intellectual ... breast cancer detection. Over many decades, XDATA has ... automatically capturing and combining ultrasound and X-ray mammography ... patents, leading companies and research hospitals including GE, ...
    Cached Medicine Technology:USP Hospitales of Spain to Offer Interleukin Genetics' Heart Health Test Throughout Its Hospital Network 2USP Hospitales of Spain to Offer Interleukin Genetics' Heart Health Test Throughout Its Hospital Network 3USP Hospitales of Spain to Offer Interleukin Genetics' Heart Health Test Throughout Its Hospital Network 4XDATA Retains Adapt IP Ventures to Market Patents and Technology for Automated 3D Ultrasound Imaging System 2
    (Date:4/26/2015)... April 26, 2015 Compare-autoinsurance.org has released a ... insurance quotes . , The easiest way to find low ... have access to the best offers online, in a simple ... different providers for information about auto insurance prices. All the ... web page. , It is now possible to compare ...
    (Date:4/26/2015)... 2015 A live auction will be ... from hospitals, surgery centers and other medical facilities around ... sold including radiology, surgery, endoscopy, lab, anesthesia, exam and ... place Tuesday, April 28th starting at 10:00am EDT. The ... 5025 North Hiatus Rd., Sunrise, FL 33351. Anyone ...
    (Date:4/26/2015)... April 26, 2015 Forbes Living ... city is one which is synonymous with clean beaches, sparkling ... and education are major economic influencers in the city on ... dynamic talk show are pleased to announce the show will ... 26 at 3:00 PM PDT. Tune in to find out ...
    (Date:4/25/2015)... Portland, ME (PRWEB) April 26, 2015 ... a Canadian based integrative healthcare event. The Integrative ... taking place October 23-24, 2015 at the Sheraton ... Healthcare Symposium Canada is one of the most ... a clinically relevant, evidenced-based CME program. The event ...
    (Date:4/25/2015)... April 25, 2015 In the United ... and above needed treatment for an illicit drug ... Substance Abuse and Mental Health Services Administration’s Survey on ... these alarming numbers are harrowing stories of men and ... abuse . David H. Kerr , founder and ...
    Breaking Medicine News(10 mins):Health News:Finding Low Cost Auto Insurance - An Online Guide Provides Tips 2Health News:Centurion Service Group to Auction off 1,200 Lots of Medical Equipment 2Health News:Forbes Living TV Will Air in San Diego, California 2Health News:Integrative Healthcare Event launching in Canada 2Health News:New Book Features Powerful Stories of People Who Overcame Addiction 2Health News:New Book Features Powerful Stories of People Who Overcame Addiction 3
    ... international team of researchers led by the University of East ... aid the early detection and diagnosis of inflammatory bowel disease. ... microscope which allows clinicians to view the bacteria that are ... disease and ulcerative colitis. "Bacteria within the wall of ...
    ... Dec. 4 (HealthDay News) -- Advances in the treatment ... according to two studies scheduled to be presented at ... Fla. Results from one study suggest that treating ... while another group of researchers are scheduled to report ...
    ... Medical Intensive Care Unit (MICU) at Vanderbilt University Medical Center for ... H1N1 flu pandemic. The tall and burly Warren County, TN, ambulance ... down and hugged some of the nurses he recognized. ... it for the next 20 days. I am just so grateful ...
    ... , FRIDAY, Dec. 3 (HealthDay News) -- ... cancer fell after doctors starting receiving lower Medicare payments ... patients with metastatic prostate cancer stayed steady, a new ... in the Journal of the National Cancer Institute ...
    ... News) -- Education and rule enforcement reduce brain and ... equipment such as headgear and mouthguards does not lower ... came to that conclusion after analyzing previous studies of ... rugby players, including six that examined the use of ...
    ... HealthDay Reporter , FRIDAY, Dec. 3 (HealthDay News) -- While good-looking ... may be at a disadvantage, a new study from Israel suggests. ... as likely to generate requests for an interview, the study found. ... percent less likely to get a response, whether or not the ...
    Cached Medicine News:Health News:Blood Cancer Advances May Improve Survival 2Health News:Blood Cancer Advances May Improve Survival 3Health News:Over-reactive immune system kills young adults during pandemic flu 2Health News:Over-reactive immune system kills young adults during pandemic flu 3Health News:Over-reactive immune system kills young adults during pandemic flu 4Health News:Medicare Cuts May Have Spurred Drop in Prostate Cancer Treatment 2Health News:Good Looks May Help Land the Interview -- for Men 2Health News:Good Looks May Help Land the Interview -- for Men 3
    Straight shafts 4 mm platform. Wide serrated handle with dull finish. Platform angled 45 degrees....
    Curved shafts with 3.5 mm angled platform and dull finish. Wide serrated handle with dull finish....
    Double-ended. 10 mm sickle shaped blade. 27 mm blunt, curved double-edged blade....
    Fixed smooth rod which slides on skin. Designated most popular model or size....
    Medicine Products: